Scripps Research Study Showcases Big Promise for COVID-19 Repurposed Drugs: But the System’s Broken & New Leadership in HHS Necessary

Scripps Research Study Showcases Big Promise for COVID-19 Repurposed Drugs: But the System's Broken & New Leadership in HHS Necessary

Scripps Research announced study results indicating 90 existing drugs or drug candidates possessing antiviral activity against SARS-CoV-2, the pathogen behind COVID-19. In what can only be described as a serious drug repurposing initiative, the top San Diego, California-based research institution identified four clinically approved drugs as well as nine compounds in other stages of clinical development with considerable potential to serve as repurposed, oral drugs targeting the coronavirus. In collaboration with the drug discovery division of the institute called Calibr, Scripps Research and a team from the venerable science-based research institute’s Department of Immunology and Microbiology tested over 12,000 drugs in two different types of human cells infected with SARS-CoV-2. TrialSite reported on a comparable study conducted by Scripps last year. In that case, Scripps announced that they identified possible COVID-19 repurposed drug candidates using their ActivPred AI Drug Discovery Platform.  Now Scripps has been at it again and the promising results of this antiviral drug discovery research were published June 3 in the journal Nature Communications. TrialSite raises an uncom...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee